<p>Japan's Takeda Pharmaceutical Co said on Friday an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays.</p>.<p>The phase 3 trial by the group, known as the CoVIg Plasma Alliance, aims to enroll 500 adult patients from the United States, Mexico and 16 other countries, according to a statement.</p>.<p>Patients will be treated with Gilead Science Inc's Remdesivir alongside the plasma treatment, which will be provided by CSL Behring, Takeda and two other companies.</p>.<p>"We are hopeful that data from the clinical trial will be available before the end of the year," Bill Mezzanotte, chief medical officer of CSL Behring, said in the release.</p>.<p><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-india-world-coronavirus-vaccine-karnataka-maharashtra-tamil-nadu-delhi-kerala-gujarat-bengal-bengaluru-mumbai-new-delhi-chennai-kolkata-cases-deaths-recoveries-AstraZeneca-Oxford-899419.html#1" target="_blank"><strong>For latest updates on Coronavirus outbreak, click here</strong></a></p>.<p>The group had aimed to begin the clinical trial in July, but it was delayed pending regulatory approval. The National Institutes of Health in the U.S. is the trial's sponsor.</p>.<p>The alliance, which also includes Germany's Biotest AG and Octapharma Plasma, is working on a hyperimmune globulin therapy derived from blood plasma. It offers a standardised dose of antibodies and doesn't need to be limited to patients with matching blood types.</p>.<p>The World Health Organization has urged caution about plasma treatments for Covid-19 saying evidence they work is "low quality", even as the United States issued emergency authorisation for such therapies.</p>.<p>Testing and production of the treatments are also vulnerable to a scarcity of blood plasma from people who have recovered from Covid-19. In its release, the CoVIg Plasma Alliance urged such individuals to consider donating their plasma. </p>
<p>Japan's Takeda Pharmaceutical Co said on Friday an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays.</p>.<p>The phase 3 trial by the group, known as the CoVIg Plasma Alliance, aims to enroll 500 adult patients from the United States, Mexico and 16 other countries, according to a statement.</p>.<p>Patients will be treated with Gilead Science Inc's Remdesivir alongside the plasma treatment, which will be provided by CSL Behring, Takeda and two other companies.</p>.<p>"We are hopeful that data from the clinical trial will be available before the end of the year," Bill Mezzanotte, chief medical officer of CSL Behring, said in the release.</p>.<p><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-india-world-coronavirus-vaccine-karnataka-maharashtra-tamil-nadu-delhi-kerala-gujarat-bengal-bengaluru-mumbai-new-delhi-chennai-kolkata-cases-deaths-recoveries-AstraZeneca-Oxford-899419.html#1" target="_blank"><strong>For latest updates on Coronavirus outbreak, click here</strong></a></p>.<p>The group had aimed to begin the clinical trial in July, but it was delayed pending regulatory approval. The National Institutes of Health in the U.S. is the trial's sponsor.</p>.<p>The alliance, which also includes Germany's Biotest AG and Octapharma Plasma, is working on a hyperimmune globulin therapy derived from blood plasma. It offers a standardised dose of antibodies and doesn't need to be limited to patients with matching blood types.</p>.<p>The World Health Organization has urged caution about plasma treatments for Covid-19 saying evidence they work is "low quality", even as the United States issued emergency authorisation for such therapies.</p>.<p>Testing and production of the treatments are also vulnerable to a scarcity of blood plasma from people who have recovered from Covid-19. In its release, the CoVIg Plasma Alliance urged such individuals to consider donating their plasma. </p>